ECSP23017158A - Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos - Google Patents

Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Info

Publication number
ECSP23017158A
ECSP23017158A ECSENADI202317158A ECDI202317158A ECSP23017158A EC SP23017158 A ECSP23017158 A EC SP23017158A EC SENADI202317158 A ECSENADI202317158 A EC SENADI202317158A EC DI202317158 A ECDI202317158 A EC DI202317158A EC SP23017158 A ECSP23017158 A EC SP23017158A
Authority
EC
Ecuador
Prior art keywords
heteroaryl
derivatives
pharmaceutical uses
substituted spiropiperidinyl
spiropiperidinyl
Prior art date
Application number
ECSENADI202317158A
Other languages
English (en)
Inventor
Gebhard Thoma
David Orain
Rudolf Wälchli
Ritesh Bhanudasji Tichkule
Andrew James Culshaw
Nancy Labbe-Giguere
Timothy Brian Hurley
David Andrew Sandham
Till Roehn
Wolfgang Miltz
Srinivasan Rajagopalan
Mallesh Bushaboina
Tajesh Patel
Xin Chen
Atwood Kim Cheung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP23017158A publication Critical patent/ECSP23017158A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo; (I) en donde R1 R2, R4 y X1 han sido definidos en la presente, a un método de elaboración de los compuestos de la invención, y a sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
ECSENADI202317158A 2020-08-14 2023-03-10 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos ECSP23017158A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20191191 2020-08-14

Publications (1)

Publication Number Publication Date
ECSP23017158A true ECSP23017158A (es) 2023-04-28

Family

ID=72088005

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202317158A ECSP23017158A (es) 2020-08-14 2023-03-10 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Country Status (20)

Country Link
US (2) US11708366B2 (es)
EP (1) EP4196478A1 (es)
JP (2) JP7545570B2 (es)
KR (1) KR20230051227A (es)
CN (1) CN116157404A (es)
AR (1) AR123241A1 (es)
AU (2) AU2021325431B2 (es)
BR (1) BR112023002031A2 (es)
CA (1) CA3185469A1 (es)
CL (1) CL2023000418A1 (es)
CO (1) CO2023002940A2 (es)
CR (1) CR20230125A (es)
DO (1) DOP2023000028A (es)
EC (1) ECSP23017158A (es)
IL (1) IL299091A (es)
MX (1) MX2023001725A (es)
PE (1) PE20230855A1 (es)
TW (1) TW202220990A (es)
UY (1) UY39377A (es)
WO (1) WO2022034529A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708366B2 (en) * 2020-08-14 2023-07-25 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998834A (en) 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
KR20040038899A (ko) 2001-09-28 2004-05-08 교와 핫꼬 고교 가부시끼가이샤 수용체 길항제
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
NZ583642A (en) 2007-09-04 2012-03-30 Biolipox Ab Bis-aromatic compounds useful in the treatment of inflammation
WO2011110824A1 (en) 2010-03-12 2011-09-15 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
CN102762567A (zh) 2009-12-21 2012-10-31 诺瓦提斯公司 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
HUE032515T2 (en) 2010-06-23 2017-09-28 Hanmi Science Co Ltd New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
CN103415513B (zh) 2011-03-14 2016-01-20 勃林格殷格翰国际有限公司 白三烯产物的苯并二氧杂环己烷抑制剂
SG10201604682VA (en) 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
JP5987220B2 (ja) 2011-07-19 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエンａ４ヒドロラーゼの阻害剤としてのアリールピラゾールエーテル
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
PL2786996T3 (pl) 2011-11-29 2017-01-31 Ono Pharmaceutical Co., Ltd. Chlorowodorowa pochodna purynonu
CA2866471A1 (en) 2012-03-06 2013-09-12 Boehringer Ingelheim International Gmbh Benzodioxanes in combination with other actives for inhibiting leukotriene production
EP2822942B1 (en) 2012-03-06 2017-05-10 Boehringer Ingelheim International GmbH Benzodioxanes for inhibiting leukotriene production
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc INHIBITORS OF BRUTON TYROSINE KINASE
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
US9708321B2 (en) 2013-02-04 2017-07-18 Merck Patent Gmbh Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
NZ711540A (en) 2013-04-25 2018-08-31 Beigene Ltd Fused heterocyclic compounds as protein kinase inhibitors
EP3022193B1 (en) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
WO2015009611A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
BR112016012794A2 (pt) 2013-12-05 2017-08-08 Acerta Pharma Bv Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
CR20160279A (es) 2013-12-20 2016-08-31 Novartis Ag Derivados de ácido heteroaril butanóico como inhibidores de lta4h
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
PL3461821T3 (pl) 2014-10-24 2020-10-19 Bristol-Myers Squibb Company Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
MX2017005719A (es) 2014-11-03 2017-12-07 Iomet Pharma Ltd Compuesto farmaceutico.
WO2016078771A1 (en) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. 1,9-diazaspiro undecane compounds having multimodal activity against pain
CA2971109A1 (en) 2014-12-24 2016-06-30 Principia Biopharma Inc. Site specific dosing of a btk inhibitor
GB201507753D0 (en) 2015-05-06 2015-06-17 Biolipox Ab New compounds and uses
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
CA3001744A1 (en) 2015-10-09 2017-04-13 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN108779095A (zh) 2015-11-04 2018-11-09 默克专利有限公司 使用具有btk抑制活性的嘧啶和吡啶化合物治疗癌症的方法
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017118277A1 (zh) 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的结晶形式及其制备方法
BR112018077503A2 (pt) 2016-06-29 2019-04-09 Principia Biopharma Inc. formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11708366B2 (en) * 2020-08-14 2023-07-25 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof

Also Published As

Publication number Publication date
MX2023001725A (es) 2023-02-22
CA3185469A1 (en) 2022-02-17
PE20230855A1 (es) 2023-05-29
AU2024200054A1 (en) 2024-01-25
JP7545570B2 (ja) 2024-09-04
US20240043425A1 (en) 2024-02-08
CO2023002940A2 (es) 2023-03-17
JP2023537357A (ja) 2023-08-31
JP2024123025A (ja) 2024-09-10
CR20230125A (es) 2023-05-11
DOP2023000028A (es) 2023-03-15
IL299091A (en) 2023-02-01
AU2021325431A1 (en) 2023-01-19
CL2023000418A1 (es) 2023-09-29
KR20230051227A (ko) 2023-04-17
US20220048909A1 (en) 2022-02-17
BR112023002031A2 (pt) 2023-03-07
EP4196478A1 (en) 2023-06-21
WO2022034529A1 (en) 2022-02-17
AU2021325431B2 (en) 2024-01-18
TW202220990A (zh) 2022-06-01
AR123241A1 (es) 2022-11-09
US11708366B2 (en) 2023-07-25
UY39377A (es) 2022-03-31
CN116157404A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
ECSP23017158A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
PA8591701A1 (es) Derivados de pirrolopirimidina
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
AR125594A1 (es) Moduladores alostéricos negativos novedosos de ciclopenta[c]pirrol de nr2b
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
UY39722A (es) Nuevos derivados de heteroaril aminopropanol
AR124982A1 (es) Macrociclos y sus usos
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR124136A1 (es) Nuevos compuestos orgánicos
AR129367A1 (es) Derivados de pirazol como agonistas de sting
AR126834A1 (es) Profármacos y derivados de psilocina y usos de estos
AR128879A1 (es) DERIVADOS DE PIRIDO-[3,4-d]PIRIDAZINA AMINA ÚTILES COMO DERIVADOS DE NLRP3
CL2022001367A1 (es) Derivados macrocíclicos de panteteína y usos de los mismos